Global Osteoarthritis Therapeutics Market Size study & Forecast, by Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Small Joint Osteoarthritis) by Drug Type (Viscosupplementation Agents, Non-steroidal Anti-inflammatory Drugs, Analge

Global Osteoarthritis Therapeutics Market Size study & Forecast, by Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Small Joint Osteoarthritis) by Drug Type (Viscosupplementation Agents, Non-steroidal Anti-inflammatory Drugs, Analgesics,Corticosteroids), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2022-2029

Global Osteoarthritis Therapeutics Market is valued approximately USD 7348.46 million in 2021 and is anticipated to grow with a healthy growth rate of more than 8.8% over the forecast period 2022-2029. One of the most prevalent chronic health disorders, osteoarthritis is characterised by persistent pain, impairment, and decreased mobility. It is a degenerative condition of the joints that worsens with time and is brought on by the deterioration and eventual loss of cartilage in one or more joints. An example of cartilage is present in the joints between bones include the knee, ankle, and elbow. It assists in lubricating the joint and lowering friction. Treatment for osteoarthritis aims to reduce pain and improve functional status. The Osteoarthritis Therapeutics market is expanding because of factors such as Increasing prevalence of osteoarthritis and Growing population susceptible to osteoarthritis.

According to Centers for Disease Control and Prevention, in year 2020, there were around 63 million people in US had diagnosed with arthritis which is expected to reach at 78 million by year 2045. Thus rising prevelance of osteoarthritis is propelling the market growth. The Journal of EClinical Medicine stated in 2020 that roughly 22% of people over 40 years of age worldwide have been diagnosed with knee osteoarthritis. According to the World Bank Group, the world old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Thus rising geriatric population in the region is further escalating the market growth. In addition, Rising number of sports injuries and development of Personalized medicines for osteoarthritis is creating a lucrative growth to the market. However, Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment and Commercialization of alternatives may hamper the market growth.

The key regions considered for the Global Osteoarthritis Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of key market players and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Pfizer, Inc
Eli Lilly and Company
Horizon Therapeutics plc
Ferring B.V.
Merck Sharp & Dohme Corp.
GlaxoSmithKline Plc.
Johnson & Johnson Private Limited
Bayer AG
Novartis AG
Pacira Pharmaceuticals, Inc

Recent Developments in the Market:
In January 2023, Arugula Sciences, LLC announced that it had received FDA permission for a Phase 1 clinical trial in the US for its first therapeutic product, Signature Cord PrimeTM. This was accomplished in partnership with its clinical partners. For patients with symptomatic knee osteoarthritis, this Phase 1 research is an open-label, dosage-ranging evaluation of safety, tolerability, preliminary effectiveness, and dose effects.
In February 2022, Alkem Laboratories announced that the Drug Controller General of India (DCGI) had approved the marketing of StemOne in India. The product is suggested for a variety of conditions, including knee osteoarthritis. It is the first allogeneic cell therapy product to be given commercial approval in India for the treatment of osteoarthritis of the knee.

Global Osteoarthritis Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Anatomy, Drug Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Anatomy offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Anatomy:
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Small Joint Osteoarthritis

By Drug Type:
Viscosupplementation Agents
Non-steroidal Anti-inflammatory Drugs
Analgesics
Corticosteroids
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Pfizer, Inc
Eli Lilly and Company
Horizon Therapeutics plc
Ferring B.V.
Merck Sharp & Dohme Corp.
GlaxoSmithKline Plc.
Johnson & Johnson Private Limited
Bayer AG
Novartis AG
Pacira Pharmaceuticals, Inc


Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.